Treatment progress on castration-resistant prostate cancer
10.3969/j.issn.1000-8179.2016.17.533
- VernacularTitle:去势抵抗性前列腺癌的治疗进展
- Author:
Qing WANG
;
Jun DU
;
Qing YANG
- Publication Type:Journal Article
- Keywords:
castration-resistant prostate cancer;
endocrinotherapy;
radiopharmaceuticals;
bone-targeting drugs;
chemotherapy
- From:
Chinese Journal of Clinical Oncology
2016;43(17):766-769
- CountryChina
- Language:Chinese
-
Abstract:
Castration-resistant prostate cancer is a fatal disease with rapid progress. This malignancy usually presents with metastasis and poor prognosis. This type of disease also often causes 100%mortality, of which the median survival time is less than 20 months. Thus, treatment of castration-resistant prostate cancer remains challenging, and the underlying mechanisms of this cancer have yet to be identified. Several new therapies for castration-resistant prostate cancer have been proposed, such as androgen receptor antago-nists, immunotherapeutic drugs, taxanes, antiangiogenic agents, radionuclides, and bone-targeting drugs. These therapies can im-prove the survival time of patients. The advances in the treatment of castration-resistant prostate cancer are briefly reviewed in this ar-ticle.
